作者
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, Alessandra Larocca, Thierry Facon, Shaji K Kumar, Massimo Offidani, Philip McCarthy, Andrea Evangelista, Sagar Lonial, Sonja Zweegman, Pellegrino Musto, Evangelos Terpos, Andrew Belch, Roman Hajek, Heinz Ludwig, A Keith Stewart, Philippe Moreau, Kenneth Anderson, Hermann Einsele, Brian GM Durie, Meletios A Dimopoulos, Ola Landgren, Jesus F San Miguel, Paul Richardson, Pieter Sonneveld, S Vincent Rajkumar
发表日期
2015/3/26
期刊
Blood, The Journal of the American Society of Hematology
卷号
125
期号
13
页码范围
2068-2074
出版商
American Society of Hematology
简介
We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive scoring system (range 0-5), based on age, comorbidities, and cognitive and physical conditions, was developed to identify 3 groups: fit (score = 0, 39%), intermediate fitness (score = 1, 31%), and frail (score ≥2, 30%). The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade ≥3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in intermediate-fitness (HR, 1.23; P = .217), and 34.0% in frail (HR, 1.74; P < .001) patients. The cumulative incidence of treatment discontinuation at 12 months was 16.5% in fit, 20.8% in intermediate-fitness (HR, 1.41; P = .052), and 31.2% in frail (HR, 2.21; P …
学术搜索中的文章
A Palumbo, S Bringhen, MV Mateos, A Larocca… - Blood, The Journal of the American Society of …, 2015